Journal article

Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study

Arnon P Kater, John F Seymour, Peter Hillmen, Barbara Eichhorst, Anton W Langerak, Carolyn Owen, Maria Verdugo, Jenny Wu, Elizabeth A Punnoose, Yanwen Jiang, Jue Wang, Michelle Boyer, Kathryn Humphrey, Mehrdad Mobasher, Thomas J Kipps

Journal of Clinical Oncology | AMER SOC CLINICAL ONCOLOGY | Published : 2019